# Glaukos Corporation (GKOS) — Stock CV

Glaukos Corporation is a $9.77B healthcare company. Revenue grew 41.5% over the last year, and it currently loses money.

> Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases.

## Identity

- **Ticker**: GKOS
- **Sector**: Healthcare
- **Industry**: Surgical & Medical Instruments & Apparatus
- **Headquarters**: ALISO VIEJO, CA
- **Employees**: 1 094
- **Website**: https://www.glaukos.com
- **Market cap**: $9.77B
- **Last price**: $165.69
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $613M
- **Net income**: -$188M
- **Free cash flow**: -$12.2M
- **Revenue growth (YoY)**: 41.5%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 15 |
| Growth | 20 |
| Profitability | 0 |
| Health | 50 |
| Quality | 30 |
| Moat | 25 |

## Qualifications (beginner checklist) — 4 of 9 passed

- [x] Revenue growing — +41.5% YoY
- [ ] Profitable — -$188M TTM
- [ ] Profit growing — -28.2% YoY
- [ ] Generates cash — -$12.2M TTM
- [x] Debt under control — current ratio 5.04
- [x] Established company — $9.77B market cap
- [ ] Not printing shares — +28.5% shares over ~5y
- [ ] Proven track record — 2/10 profitable years
- [x] Financially stable — Altman Z 23.9 — safe

## Experience (career milestones)

- **FY2019** — Best year on record: $15.4M net income
- **FY2016** — First recorded profitable year: $4.52M net income

## Strengths

- High gross margin (79.1%)
- Revenue growing 41.5% year over year
- Altman Z-Score 23.88 — low bankruptcy-risk zone

## Watch-outs

- Not profitable — 30.7% net margin
- Negative free cash flow (-$12.2M)
- Thin interest coverage (-28.9×)
- Loss-making in 8 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $294M | -$49.6M | -$23.1M |
| FY2022 | $283M | -$99.2M | -$63.4M |
| FY2023 | $315M | -$135M | -$78.0M |
| FY2024 | $383M | -$146M | -$67.6M |
| FY2025 | $507M | -$188M | -$22.5M |

---

Source: https://stockcv.com/GKOS — derived from company filings; may be delayed or incomplete. Information, not investment advice.